quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:57·708d
NEWSRelease
First Wave BioPharma Inc. logo

First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease

FWBI· First Wave BioPharma Inc.
Health Care
Original source

Companies

  • FWBI
    First Wave BioPharma Inc.
    Health Care

Recent analyst ratings

  • Dec 7UpdateMaxim Group-

Related

  • SEC708d
    First Wave BioPharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR708d
    First Wave BioPharma Changes Name to Entero Therapeutics
  • SEC709d
    SEC Form 10-Q filed by First Wave BioPharma Inc.
  • SEC710d
    First Wave BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC710d
    SEC Form 424B5 filed by First Wave BioPharma Inc.
  • NEWS714d
    First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
  • PR714d
    First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
  • PR715d
    First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022